GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (XBRU:ALIMG) » Definitions » EV-to-EBITDA

DMS Imaging (XBRU:ALIMG) EV-to-EBITDA : 23.99 (As of May. 04, 2024)


View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DMS Imaging's enterprise value is €48.51 Mil. DMS Imaging's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €2.02 Mil. Therefore, DMS Imaging's EV-to-EBITDA for today is 23.99.

The historical rank and industry rank for DMS Imaging's EV-to-EBITDA or its related term are showing as below:

XBRU:ALIMG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.23   Med: -0.63   Max: 24.36
Current: 23.99

During the past 12 years, the highest EV-to-EBITDA of DMS Imaging was 24.36. The lowest was -58.23. And the median was -0.63.

XBRU:ALIMG's EV-to-EBITDA is ranked worse than
73.81% of 462 companies
in the Biotechnology industry
Industry Median: 9.55 vs XBRU:ALIMG: 23.99

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), DMS Imaging's stock price is €0.024. DMS Imaging's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.001. Therefore, DMS Imaging's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


DMS Imaging EV-to-EBITDA Historical Data

The historical data trend for DMS Imaging's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging EV-to-EBITDA Chart

DMS Imaging Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.53 -10.69 7.70 -74.16 23.62

DMS Imaging Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.70 - -74.16 - 23.62

Competitive Comparison of DMS Imaging's EV-to-EBITDA

For the Biotechnology subindustry, DMS Imaging's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMS Imaging's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DMS Imaging's EV-to-EBITDA falls into.



DMS Imaging EV-to-EBITDA Calculation

DMS Imaging's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=48.513/2.022
=23.99

DMS Imaging's current Enterprise Value is €48.51 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DMS Imaging's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €2.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DMS Imaging  (XBRU:ALIMG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

DMS Imaging's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.024/-0.001
=At Loss

DMS Imaging's share price for today is €0.024.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DMS Imaging's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.001.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


DMS Imaging EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DMS Imaging's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


DMS Imaging (XBRU:ALIMG) Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (XBRU:ALIMG) Headlines

No Headlines